Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Remsima is indicated for:
Pharmacology
Infliximab works by binding with high affinity to both the soluble and the transmembrane forms of TNFα. This stops TNFα from attaching to its receptors, so its biological activity is neutralized. Infliximab does not neutralize TNFα (lymphotoxin-α), which is a related cytokine that uses the same receptors as TNFα.
TNFα has several biological activities. These include inducing pro inflammatory cytokines such as interleukins (IL) 1 and 6, and increasing leukocyte migration by raising endothelial layer permeability and the expression of adhesion molecules by endothelial cells and leukocytes. TNFα also activates the functional activity of neutrophils and eosinophils. It induces acute phase reactants and other liver proteins, as well as tissue degrading enzymes produced by synoviocytes and/or chondrocytes.
Cells that express transmembrane TNFα and have infliximab bound to them can be lysed in vitro or in vivo. In a wide variety of in vitro bioassays using human fibroblasts, endothelial cells, neutrophils, B and T lymphocytes and epithelial cells, infliximab inhibits the functional activity of TNFα. How these biological response markers relate to the way infliximab produces its clinical effects is unknown.
In animal studies, anti-TNFα antibodies reduce disease activity in the cotton-top tamarin colitis model, and decrease synovitis and joint erosions in a murine model of collagen-induced arthritis. Infliximab prevents disease in transgenic mice that develop polyarthritis because of constitutive expression of human TNFα. When it is given after the disease has started, eroded joints are able to heal.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Crohn's disease: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Some adult patients who respond at first may benefit from a dose increase to 10 mg/kg if they later lose that response.
Pediatric Crohn's disease: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
Ulcerative colitis: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
Pediatric ulcerative colitis: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
Rheumatoid arthritis: given together with methotrexate, 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Some patients may benefit from a dose of up to 10 mg/kg, or from treatment as often as every 4 weeks.
Ankylosing spondylitis: 5 mg/kg at 0, 2 and 6 weeks, then every 6 weeks.
Psoriatic arthritis and plaque psoriasis: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
Side Effects
The most common side effects of infliximab, seen in more than 10% of people, are infections (for example upper respiratory infections, sinusitis and pharyngitis), infusion-related reactions, headache and abdominal pain.
Cautions & Contraindications
Warnings & Precautions
Don't give Infliximab during an active infection. If an infection develops, monitor the patient carefully and stop the medicine if the infection becomes serious. Invasive fungal infections: if a patient develops a systemic illness while on treatment, consider empiric antifungal therapy for those who live in or travel to regions where mycoses are endemic. Malignancies: the incidence of malignancies, including lymphoma, was greater in patients treated with Infliximab than in controls. Because of the risk of HSTCL, assess the risk and benefit carefully, especially if the patient has Crohn's disease or ulcerative colitis, is male, and is receiving azathioprine or 6-mercaptopurine treatment. Hepatitis B virus reactivation: test for HBV infection before starting treatment. Monitor HBV carriers during therapy and for several months after it. If reactivation occurs, stop the medicine and begin anti-viral therapy. Hepatotoxicity: severe hepatic reactions are rare, but some have been fatal or have needed a liver transplant. Stop the medicine in cases of jaundice and/or marked liver enzyme elevations. Heart failure: new onset or worsening symptoms may occur. Cytopenias: advise patients to seek immediate medical attention if signs and symptoms develop, and consider stopping the medicine. Hypersensitivity: serious infusion reactions, including anaphylaxis or serum sickness-like reactions, may occur. Demyelinating disease: exacerbation or new onset may occur. Lupus-like syndrome: stop the medicine if the syndrome develops. Live vaccines or therapeutic infectious agents should not be given with Infliximab. Bring pediatric patients
Contraindications
Infliximab should not be given at doses above 5 mg/kg to people with moderate to severe heart failure. It is also not for anyone who has had a severe hypersensitivity reaction to Infliximab before, or who is known to be hypersensitive to any of its inactive components or to any murine proteins.
Pregnancy & Breastfeeding
Infliximab is listed as Pregnancy Category B. Doctors don't know whether Infliximab can harm an unborn baby when it is given to a pregnant woman, or whether it can affect the ability to have children.
It is also not known whether Infliximab passes into human milk, or whether the baby's body absorbs it after swallowing. Many drugs and immunoglobulins do pass into human milk, and Infliximab could cause adverse reactions in nursing infants. So women should not breast-feed their infants while taking Infliximab.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Use in Special Populations
Use in children: Infliximab has not been studied in children younger than 6 years who have Crohn's disease or ulcerative colitis.
Storage
Keep Infliximab in a refrigerator at 2ºC to 8ºC. Check the expiry date (Exp) printed on the carton and on the vial, and don't use the medicine after that date. Infliximab has no preservative in it.
Common questions about Remsima 100 mg/20 ml
What is Remsima 100 mg/20 ml Intravitreal Injection?
Remsima 100 mg/20 ml Intravitreal Injection is a medicine that contains Infliximab. It is made by ZAS Corporation. It belongs to the Targeted Cancer Therapy group of medicines.
What is Remsima used for?
Remsima is used for: Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriasis.
What are the side effects of Remsima?
The most common side effects of infliximab, seen in more than 10% of people, are infections (for example upper respiratory infections, sinusitis and pharyngitis), infusion-related reactions, headache and abdominal pain.
Can I take Remsima during pregnancy or while breastfeeding?
Infliximab is listed as Pregnancy Category B. Doctors don't know whether Infliximab can harm an unborn baby when it is given to a pregnant woman, or whether it can affect the ability to have children. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Remsima?
Keep Infliximab in a refrigerator at 2ºC to 8ºC. Check the expiry date (Exp) printed on the carton and on the vial, and don't use the medicine after that date.
Do I need a prescription for Remsima?
Remsima is a prescription (Rx) medicine. Take it as your doctor advises.